Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $12.40.
INO has been the subject of a number of recent analyst reports. Oppenheimer decreased their target price on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an "outperform" rating for the company in a research report on Monday, November 18th. HC Wainwright decreased their price objective on shares of Inovio Pharmaceuticals from $5.00 to $3.00 and set a "neutral" rating for the company in a research report on Monday, January 13th. Royal Bank of Canada dropped their target price on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a "sector perform" rating on the stock in a report on Friday, November 15th. Finally, JMP Securities reiterated a "market outperform" rating and set a $18.00 price target on shares of Inovio Pharmaceuticals in a report on Friday, January 10th.
Get Our Latest Stock Report on INO
Institutional Investors Weigh In On Inovio Pharmaceuticals
A number of large investors have recently bought and sold shares of the stock. Alpine Global Management LLC acquired a new position in shares of Inovio Pharmaceuticals during the fourth quarter valued at about $31,000. BNP Paribas Financial Markets boosted its holdings in Inovio Pharmaceuticals by 177.0% in the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 3,630 shares in the last quarter. Bank of Montreal Can acquired a new stake in Inovio Pharmaceuticals in the fourth quarter valued at approximately $43,000. Boothbay Fund Management LLC bought a new stake in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $44,000. Finally, Barclays PLC increased its holdings in shares of Inovio Pharmaceuticals by 15.0% during the fourth quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 5,111 shares in the last quarter. 26.79% of the stock is currently owned by institutional investors and hedge funds.
Inovio Pharmaceuticals Price Performance
NASDAQ:INO traded up $0.09 during trading hours on Friday, hitting $1.93. The company's stock had a trading volume of 474,538 shares, compared to its average volume of 548,962. The company has a market capitalization of $50.24 million, a P/E ratio of -0.91 and a beta of 0.89. Inovio Pharmaceuticals has a twelve month low of $1.74 and a twelve month high of $14.75. The stock has a fifty day simple moving average of $2.02 and a 200-day simple moving average of $4.19.
About Inovio Pharmaceuticals
(
Get Free ReportInovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Further Reading
Before you consider Inovio Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.
While Inovio Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
